Dren Bio is a privately held, clinical-stage biopharmaceutical company pioneering novel antibody therapeutics that selectively deplete pathogenic cells and other disease-causing agents.
The target
Pathogenic cells, protein aggregates and other disease-causing agents drive cancer, autoimmune disease and neurological disease. The challenge is removing them without harming what surrounds them.
The engager
Our bispecific antibodies bind a disease target with one arm and a novel phagocytic receptor, selectively expressed on myeloid cells, with the other.
The depletion
Myeloid cells switch on only in the presence of the target antigen, then engulf and clear it. A design that may offer greater therapeutic indexes than T-cell engagers or ADCs.
The response
After phagocytosis, myeloid cells cross-present antigens, priming the adaptive immune system to potentially elicit deep and durable responses.
Two wholly owned clinical programs are being evaluated across oncology and autoimmune disease, backed by a deep preclinical pipeline in oncology, immunology and neurology.
| Program | Therapeutic area | Development stage |
|---|---|---|
| DibotatugDR-01Selective autoreactive cell depletion | Hematologic Malignancies | Phase 2 |
| Autoimmunity | Phase 1 | |
| DR-0202Myeloid engagerTargeted Myeloid Engager and Phagocytosis Platform | Solid Tumors | Phase 1 |
2025 Prix Galien USA Award, Best Biotech Startup
“Among the many emerging myeloid-targeting strategies, their Targeted Myeloid Engager and Phagocytosis Platform is one of the most exciting developments in the field today.”
Every team member plays a key role in our mission to improve the lives of patients.
See open roles